Evaluation of cytological diagnostic accuracy for canine splenic neoplasms : an investigation in 78 cases using STARD guidelines by M. Tecilla et al.
RESEARCH ARTICLE
Evaluation of cytological diagnostic accuracy
for canine splenic neoplasms: An investigation
in 78 cases using STARD guidelines
Marco Tecilla☯, Matteo GambiniID☯*, Annalisa Forlani¤, Mario Caniatti, Gabriele Ghisleni,
Paola Roccabianca
Diagnostic Pathology Service, Dipartimento di Medicina Veterinaria (DIMEVET), Università degli Studi di
Milano, Lodi, Italy
☯ These authors contributed equally to this work.
¤ Current address: IDEXX Laboratories, Wetherby, West Yorkshire, United Kingdom
* matteo.gambini@unimi.it
Abstract
Cytology represents a useful diagnostic tool in the preliminary clinical approach to canine
splenic lesions, and may prevent unnecessary splenectomy. However, few studies have
evaluated diagnostic accuracy of cytology in the diagnosis of canine splenic neoplasms.
The aim of this study was to determine overall accuracy, sensitivity, specificity, positive and
negative predictive values (i.e. diagnostic accuracy indexes) of cytology for canine splenic
neoplasms following Standards for the Reporting of Diagnostic Accuracy Studies (STARD)
guidelines. A consecutive series of canine splenic cytological samples was retrospectively
retrieved from the database of the Diagnostic Pathology Service of the Department of Veter-
inary Medicine (DIMEVET—University of Milan). Histopathology was set as the diagnostic
reference standard. Cytological cases were enrolled when slides were available for review
and when the same lesion was submitted for histopathology. Seventy-eight (78) lesions
were included in the study. By histopathology, 56 were neoplastic and 22 were non-neoplas-
tic. Cytology had an overall accuracy of 73.08% (95% C.I. 61.84%-82.50%), sensitivity of
64.29% (95% C.I. 50.36%-76.64%), specificity of 95.45% (95% C.I. 77.16%-99.88%), and
positive and negative predictive values of 97.3% (95% C.I. 84.01%-99.60%) and 51.22%
(95% C.I. 42.21%-60.15%), respectively. Low sensitivity and negative predictive value were
balanced by very high specificity and positive predictive value. When positive for neoplasia,
cytology represents a useful diagnostic tool to rule in splenic neoplasia, prompting surgery
independently from other diagnostic tests. Conversely, a negative cytological result requires
additional investigations to confirm the dog to be disease free.
Introduction
Ultrasonographic examination of nodular splenic lesions in dogs is not reliable to differentiate
with certainty benign and malignant processes, necessitating the use of additional, ideally min-
imally invasive, diagnostic tests [1]. Hemangiosarcoma (HES) is the most common primary
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splenic malignant tumor of dogs [2]. Still, HES represents fewer than 25% of overall splenic
lesions [3] with up to 74% of dogs being diagnosed with benign lesions [4] such as hematoma
and hyperplasia [2,5]. However, due to the poor prognosis associated with HES, splenectomy
is still the routine approach to most canine splenic masses for both diagnostic and therapeutic
purposes [6–8].
While the two-month post-splenectomy survival rate is lower in dogs with HES (32%) com-
pared to dogs with hematomas (83%), the general survival rate after splenectomy is 52%,
regardless of underlying splenic pathology [3]. While this can be interpreted as fair survival
data, a proportion of dogs (7.6%) will develop complications secondary to splenectomy
because of thrombotic or coagulopathic syndromes [9]. Additional adverse effects following
splenectomy in dogs have included peri- and post-operative ventricular arrhythmias [9–11],
reduced blood filtration and renewal [12,13], impairment of humoral immune response [14],
reduced immune-surveillance against bacteria and parasites [15–19], and higher incidence of
gastric dilatation-volvulus [6,20–22]. For these reasons, any preoperative diagnostic approach
to splenic lesions, including cytology, may be beneficial in preventing unnecessary splenec-
tomy. Notwithstanding the common belief that splenic aspiration can be dangerous especially
when investigating cavitated masses [6,7,23], complications from splenic aspiration proce-
dures are rarely elicited even in thrombocytopenic animals [8,24–26]. For comparison, in
human medicine splenic fine needle aspiration (FNA) cytology is seldom associated with com-
plications [27,28], resulting in 5.2% secondary complications with fewer than 1% considered
severe and consisting mostly of controllable hemorrhage [29].
Thus, attempts to minimize unnecessary splenectomy should prompt an increased use of
additional diagnostic techniques as preoperative screening tests to characterize splenic disease.
Fine needle aspiration cytology can provide diagnostic information useful to distinguish
inflammatory, benign and malignant nodular lesions and to assess generalized splenomegaly
[7,24,30].
Despite the relatively high frequency of splenic diseases in dogs, data regarding usefulness
and validity of diagnostic cytology are fragmentary. In veterinary medicine, no studies have
comprehensively assessed overall accuracy, sensitivity, specificity, positive and negative predic-
tive values of canine splenic cytology against histopathology utilizing the Standards for the
Reporting of Diagnostic Accuracy Studies (STARD) guidelines [8,23–25,31–33]. STARD
guidelines have been created to avoid incomplete reporting in diagnostic accuracy studies and
to improve the general quality of the latter, reducing problems related to study identification,
critical appraisal, and replication [34]. Overall agreement between cytology and histology of
canine splenic lesions is the most frequent index reported, ranging from 38 to 100% [8,23–
25,31–33]. Specifically, this index has been evaluated on a limited number of splenic cytologi-
cal specimens (range 5–40) [8,23–25,31–33]. In most reports, sensitivity, specificity, positive
and negative predictive values of splenic cytology are not calculated and cannot be properly
estimated [8,23–25,31–33] because caseloads simultaneously include multiple species
[24,25,31–33], multiple tissues and organs [31–33], or “equivocal” or “provisional” cytological
and histological diagnoses [23,24,33]. Application of STARD guidelines in the current study
allowed cross-tabulation of cytological results (i.e. the index test) against those of histopathol-
ogy (i.e. the reference standard) to generate sensitivity and specificity data [34]. These data
have not been included in previous studies and will be useful for future researchers comparing
diagnostic methods for canine splenic neoplasms.
To avoid unnecessary splenectomy, a diagnostic test with a high sensitivity and negative
predictive value is desirable because these indexes measure the percentage of diseased dogs
correctly diagnosed with splenic neoplasia and the probability that dogs with a negative cytol-
ogy truly do not have a neoplasm, respectively. In this context, the aim of this study was to
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determine the diagnostic accuracy of cytology in the diagnosis of canine splenic neoplasms uti-
lizing the corresponding histopathology as the diagnostic reference standard [24,31,33,35,36],
following STARD guidelines [34]. Additionally, sensitivity of cytology in the diagnosis of spe-
cific tumor types and in the identification of nodular versus diffuse neoplasms was evaluated.
Materials and methods
Criteria of selection of cases
In this retrospective study, the electronic cytological database of the Diagnostic Pathology
Service of the Department of Veterinary Medicine (DIMEVET) of the University of Milan
was searched for splenic samples collected between January 1st 1998 to January 31st 2018. The
database was searched for specific key words in the following combinations: 1) “dog” and
“spleen”, 2) “dog” and “splenic”. A consecutive series of canine splenic cytologies was
obtained. Cytological samples came from external referring private practices or from the Vet-
erinary Teaching Hospital (VTH) of the DIMEVET, or were prepared from fresh surgical
biopsies and necropsies. Samples were submitted or collected to evaluate splenomegaly or
nodular lesions.
The histopathology database was then searched for the histopathology corresponding to the
same lesion examined by cytology. Histopathological samples were obtained from splenic
biopsies (nodular lesions) or whole spleens (from splenectomies or necropsies) submitted to
the Diagnostic Pathology Service of the DIMEVET, or were represented by slides submitted by
external pathologists as second opinion cases. A time interval>45 days between cytological
and histological sampling was an exclusion criterion. Histopathological samples collected via
needle core biopsies were excluded from the study as they may bear reduced diagnostic reli-
ability compared to incisional and excisional histological samples [8,37]. Cases were included
in the study only when cytological and histological slides of the same lesion were available for
review.
Additional information collected from the archives for cases included in the study were:
sex, age, breed, cytological sampling technique (e.g. fine needle aspiration–FNA, touch
imprint, scraping) and gross appearance of the lesion (i.e. diffuse versus nodular lesion).
To improve data completeness, transparency, and reproducibility, the study was con-
ducted following the STARD guidelines [34] to the best of authors’ ability. All canine splenic
samples included in the current retrospective work, regardless of the sampling technique
applied, were submitted to the Diagnostic Pathology Service of the DIMEVET for diagnostic
purposes of spontaneous developing diseases. No animals were sampled or euthanized for
research use. The use of animal tissue in the current study was approved by the Ethics Com-
mittee in charge for animal welfare of the University of Milan (Organismo Preposto al Bene-
ssere degli Animali, OPBA) with protocol number OPBA_86_2019. Sensitive information
regarding owners and animals were stored, managed and preserved according to European
and Italian laws.
Sample processing
Cytological samples were air dried and stained with May-Gru¨nwald-Giemsa (Merck KGaA,
Frankfurt, Germany). Tissue samples for histopathology were fixed in 10% neutral buffered
formalin, processed routinely, and embedded in paraffin wax. Sections of 5 μm were stained
with Hematoxylin and Eosin. Second opinion cases were provided as Hematoxylin and Eosin
stained slides by the referring pathologists.
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Case review
All cytological and histopathological samples were independently reviewed in a blinded fash-
ion by three cytologists (M.C.—ECVP, G.G.—ECVCP, M.G.—resident) and by three anatomi-
cal pathologists (A.F.–ECVP, P.R.—ECVP, M.T.—resident), respectively. Both cytologists and
anatomical pathologists were blinded to signalment information related to each case.
For each cytological case, one slide for each sampling technique was reviewed. First, slides
were examined at low-power magnification (i.e. 10x objective lens) to assess the adequacy of
the specimen. Poorly cellular samples were those characterized by marked hemodilution in the
absence of both stromal elements and a mixed population of leukocytes [30]. Poorly cellular
samples, poorly smeared samples (i.e. too thick or where most cells were ruptured), and sam-
ples where stain quality impaired adequate definition of the cell type (e.g. formalin-contami-
nated smears), were considered inconclusive [30]. Inconclusive cases were excluded from the
statistical analysis as previously reported [8,24,32,33,35–37].
Cytological diagnoses were expressed according to those reported in the literature
[4,30,38,39]. To facilitate comparison of the agreement between cytological and histological
results, each cytological sample was further classified as neoplastic or non-neoplastic according
to the main pathologic process. Non-neoplastic samples were those characterized by degenera-
tive, reactive (including extramedullary hematopoiesis) [23,30], and inflammatory changes, as
well as normal specimens consisting of stromal elements with mixed leukocyte population
[30,38]. Reviewing cytologists were not allowed to use diagnostic modifiers such as “probably”,
“most likely”, “suggestive of”, as previously reported [37], nor to provide equivocal diagnoses
(i.e. reporting more than one differential diagnosis). When a univocal diagnosis was not
reached, cytologists reviewed the case collaboratively to find an agreement. Only the definitive
diagnosis was included in the consecutive statistical analysis.
Neoplastic cytological samples were further subdivided by tumor type into the following
subcategories: benign soft tissue tumor (BSTT) including angioma, angiosarcoma (HES), soft
tissue sarcoma (STS) excluding angiosarcoma, lymphoma (LYM), mast cell tumor (MCT), his-
tiocytic tumors including hemophagocytic sarcoma (HS), other round cell tumors including
plasma cell tumor, myeloid leukemia and undifferentiated round cell tumor (ORCT), carci-
noma (CARC), malignant neoplasm not otherwise specified (MNNOS).
Cases were included only when the three anatomical pathologists were in agreement
because histopathology served as the diagnostic reference standard to evaluate cytological
diagnostic accuracy. Neoplasms were classified applying the World Health Organization’s his-
tologic classification of tumors in domestic animals [40–48]. To further standardize histopath-
ological diagnoses, anatomic pathologists were invited to classify some specific pathological
entities (i.e. lymphomas, histiocytic proliferative disorders, nodular lesions previously classi-
fied as “fibrohistiocytic nodules”) according to criteria reported in recent literature [49–52].
For nodular lesions, histological samples were considered conclusive and therefore only
included in the statistical analysis if at least one slide containing at least one margin between
the nodule and the adjacent splenic parenchyma was available for review [2,3,5].
Histological samples were then classified as neoplastic and non-neoplastic. Neoplastic cases
were further subdivided utilizing the same subcategories applied to cytological samples.
Data analysis
For all cases, the cytological diagnosis was compared with its paired histopathological diagno-
sis. Since histological samples maintain tissue architecture and are not biased by cellularity
[8,32,37,53], histopathology was set as the reference standard as previously reported
[24,31,33,35,36].
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To determine diagnostic accuracy indexes, cytological specimens were classified according
to four correlation categories (true positive, true negative, false positive, false negative). Specifi-
cally, the True Positive (TP) category included all cytological samples diagnosed as neoplastic
with a corresponding neoplastic histopathology. The True Negative (TN) category comprised
all cytological samples diagnosed as non-neoplastic with a corresponding non-neoplastic his-
topathology. The False Positive (FP) category included all cytological samples diagnosed as
neoplastic with a corresponding non-neoplastic histopathology. The False Negative (FN) cate-
gory comprised all non-neoplastic cytological diagnoses with a corresponding neoplastic
histopathology.
To evaluate the sensitivity of cytology in the diagnosis of specific tumor types, only those
cases histologically confirmed as neoplastic were taken into account. The subcategories
assigned to each cytological and corresponding histological sample were then compared.
When cytological and histological diagnoses matched for both neoplastic categorization and
tumor type subcategorization, the case was defined as “true positive with complete agreement”.
When cytological and histological diagnoses matched for the neoplastic categorization but did
not match for the tumor type subcategorization, the case was defined as “true positive with
partial agreement”. When a histopathological diagnosis categorized as neoplastic corre-
sponded to a cytological diagnosis categorized as non-neoplastic, the case was considered in
disagreement and defined as “false negative case”.
Statistical methods
Cytological-histological correlation categories (TP, FP, TN, FN) were included in a 2x2 table
and used to calculate point estimates of overall accuracy, sensitivity, specificity, positive and
negative predictive values [36,54]. Overall accuracy was defined as the ability of cytology to
correctly identify neoplastic and non-neoplastic lesions, and was calculated as the sum of cases
in which cytology and histology agreed in diagnosing a lesion as neoplastic (i.e. TP) or non-
neoplastic (i.e. TN), divided by the total number of cases included in the study [32,55]. Given
that pre-determined acceptability criteria for diagnostic performance of splenic cytology to
distinguish between neoplastic and non-neoplastic lesions have not been previously estab-
lished, overall accuracy, sensitivity, specificity, positive and negative predictive values were
considered low if<70%, moderate if�70% and<80%, high if�80% and<90%, and very
high if�90% [54]. To increase data comparability with other studies, positive and negative
likelihood ratios were calculated [36]. Ninety-five percent (95%) confidence interval was calcu-
lated for each of the above mentioned indices of diagnostic test accuracy using a web-based
application (MEDCALC—https://www.medcalc.org/calc/diagnostic_test.php).
The level of agreement between cytology and histopathology in the diagnosis of splenic neo-
plastic conditions was further investigated calculating the Cohen’s kappa coefficient (κ), which
was then corrected by the standard error. The value of k can be indicative of no agreement (if
k<0), slight agreement (k = 0–0.20), fair agreement (k = 0.21–0.40), moderate agreement
(k = 0.41–0.60), substantial agreement (k = 0.61–0.80), almost perfect agreement (k = 0.81–
0.99), or perfect agreement (k = 1) [36,54]. Cohen’s kappa and standard error were calculated
utilizing GraphPad QuickCalcs Web site (GraphPad Inc.—https://www.graphpad.com/
quickcalcs/kappa2/).
Sensitivity of cytology in differentiating splenic tumor types was defined as the ability of
cytology to correctly identify as neoplastic a sample belonging to a specific neoplastic subcate-
gory. Therefore, sensitivity for each tumor type was calculated as the sum of cases in complete
and partial agreement (i.e. true positive cases) divided by the total number of cases with that
specific neoplasm [31].
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Similarly, the sensitivity of cytology in the diagnosis of neoplastic lesions according to
their distribution pattern (i.e. diffuse or nodular) was evaluated. For each distribution pat-
tern, sensitivity was calculated as the sum of cases in complete and partial agreement (i.e.
true positive) divided by the total number of cases with a specific distribution pattern.
Sensitivity of cytology according to distribution pattern was calculated for neoplastic
lesions in general (i.e. the general sensitivity value obtained in our study), as well as for those
specific neoplastic subcategories including cases with either diffuse or nodular distribution
pattern.
Chi-square analysis applied to pairwise comparison was performed to evaluate whether sta-
tistically significant differences existed in the sensitivity of cytology for different tumor types,
as well as in the diagnosis of neoplastic lesions with diffuse or nodular distribution pattern
[36,37]. Specifically, the sensitivity of cytology for each neoplastic subcategory was compared
with the sensitivity for splenic neoplasms in general, the sensitivity for all other neoplastic sub-
categories, and the sensitivity for any other neoplastic subcategory. Similarly, the difference
between sensitivity for nodular or diffuse lesions among neoplasm in general and for each
neoplastic subcategory was statistically investigated. Chi-square analysis was performed only
on sensitivity values different from 0% and 100%, using MEDCALC (https://www.medcalc.




From a total of 950 splenic cytological samples retrieved between 1998–2018, 92 cytological
samples from 91 dogs were included in the study; one dog was sampled for two distinct splenic
lesions. A total of 858 splenic cytological cases were excluded for the following reasons: lack of
a corresponding histopathological sample (832 cases), unavailable cytological and/or histologi-
cal samples (16 cases), and needle core biopsies (10 cases). Among the selected cytological
cases, 14 were considered inconclusive, and therefore excluded from the consecutive statistical
analysis. Detailed evaluation of diagnostic accuracy was performed on 78/92 reviewed cytolog-
ical samples (retrieval rate: 84.78%) obtained from 77 dogs [37].
Sex was available for 76/77 dogs: 19 were spayed females, 6 neutered males, 21 intact
females, and 30 intact males. Mean age was 9.05 years (age range 2 months-16 years; age was
not available for 2 cases). Twenty-six (26) breeds other than mongrels were represented; in one
case breed was not provided.
The time interval between cytological sampling and corresponding histopathology collec-
tion ranged from 0 to 44 days for all cases.
Of the 78 cases included in the study, 81 cytological slides were evaluated (3 cases were sam-
pled with two different techniques, i.e. touch imprinting and scraping). Cytological samples
consisted of 43/81 touch imprints (53.09%) collected from both surgical biopsies and necrop-
sies, 28 FNAs (34.57%), of these 21 were ultrasound guided, 1 was CT-scan guided, 1 was
obtained during surgery, while in 5 FNA biopsies no additional sampling information was
available. In 6 cases scrapings were obtained from surgical and necropsy specimens (7.41%).
In 4 cases (4.94%) the sampling technique was not specified.
Complete agreement among anatomical pathologists was reached for all the 78 correspond-
ing histopathological samples. Histopathological specimens were distributed as follows: 51 sur-
gical samples from partial or complete splenectomies (51/78 cases, 65.38%), 24 spleens from
necropsies (24/78, 30.77%), and 3 cases submitted as a second opinion (3/78, 3.85%).
Cytological diagnostic accuracy and canine splenic neoplasms
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Cytological and histological diagnoses
All cytological and corresponding histopathological diagnoses (78 cases) are listed in S1 Table.
The diagnoses for the cytological-histological pairs excluded due to inconclusive cytology are
listed in S2 Table.
No diagnostic differences were found for samples collected using two different sampling
techniques, and therefore they were considered as one case in the consecutive statistical analy-
sis. Cytologically, 37/78 cases were diagnosed as neoplastic (47.44%) and 41/78 as non-neo-
plastic (52.56%). All cases diagnosed as neoplastic were classified as malignant, and indeed, no
benign neoplasms were cytologically observed.
Histologically, 56/78 cases (71.79%) were neoplastic (S1 Table) and 22/78 cases (28.21%)
were non-neoplastic. Malignant tumors were 51 (51/56 tumors, 91.07%) and 5 were benign.
The prevalence of each tumor type is reported in Table 1. No malignant neoplasm not other-
wise specified was included in the study.
Of the 78 splenic lesions, 60 were nodular (76.92%), and 17 were diffuse (21.79%), while no
information regarding the distribution pattern was available for 1 case (1.28%). Of the 56 neo-
plastic lesions, 43/56 cases (76.79%) were nodular and 12 cases (21.43%) were diffuse. The case
for which distribution pattern was not provided was a liposarcoma (1.79%). This case was
excluded from the evaluation of cytology sensitivity according to neoplasm distribution pat-
tern. The proportion of cases with nodular or diffuse pattern for each tumor type are reported
in Table 2.
Table 1. Prevalence, agreement levels and sensitivity of cytology in the diagnosis of each neoplastic subcategory.
Prevalence TP cases with complete agreement TP cases with partial agreement FN cases Sensitivity Confidence Interval (95%)
TOTAL 71.79% (56/78) 42.86% (24/56) 21.43% (12/56) 35.71% (20/56) 64.29% 50.36%–76.64%
HES 28.57% (16/56) 68.75% (11/16) 6.25% (1/16) 25% (4/16) 75% 47.62%–92.73%
LYM 28.57% (16/56) 37.50% (2/16) 12.50% (6/16) 50% (8/16) 50% 24.65%–75.35%
STS 12.50% (7/56) 42.86% (3/7) 28.57% (2/7) 28.57% (2/7) 71.43% 29.04%–96.33%
BSTT 8.93% (5/56) 0% (0/5) 0% (0/5) 100% (5/5) 0% 0.00%–52.18%
HS 7.14% (4/56) 25% (1/4) 50% (1/4) 25% (1/4) 75% 19.41%–99.37%
MCT 7.14% (4/56) 100% (4/4) 0% (0/4) 0% (0/4) 100% 39.76%–100%
CARC 5.36%(3/56) 66.67% (2/3) 33.33% (1/3) 0% (0/3) 100% 29.24%–100%
ORCT 1.79% (1/56) 0% (0/1) 100% (1/1) 0% (0/1) 100% 2.50%–100%
BSTT, benign soft tissue tumor including angioma; CARC, carcinoma; FN, false negative; HES, angiosarcoma; HS, histiocytic neoplasm (including hemophagocytic
syndrome); LYM, lymphoma; MCT, mast cell tumor (MCT); ORCT, other round cell tumor; STS, soft tissue sarcoma other than angiosarcoma; TP, true positive.
https://doi.org/10.1371/journal.pone.0224945.t001
Table 2. Prevalence, agreement levels and sensitivity of cytology in the diagnosis of each neoplastic subcategory on the basis of distribution pattern.
Nodular Diffuse
# of cases TP FN Sensitivity
(95% CI)
# of cases TP FN Sensitivity
(95% CI)
TOTAL 43/56 (76.79%) 26/43 17/43 60.47%
(44.41%–75.02%)
12/56 (21.43%) 9/12 3/12 75%
(42.81%–94.51%)
HES 14/16 (87.50%) 10/14 4/14 71.43%
(41.90%–91.61%)
2/16 (12.50%) 2/2 0/2 100%
(15.81%–100%)
LYM 10/16 (62.50%) 5/10 5/10 50%
(18.71%–81.29%)
6/16 (37.50%) 3/6 3/6 50%
(11.81%–88.19%)
MCT 1/4 (25%) 1/1 0/1 100%
(2.50%–100%)
3/4 (75%) 3/3 0/3 100%
(29.24%–100%)
CI, confidence interval; FN, false negative; HES, angiosarcoma; LYM, lymphoma; MCT, mast cell tumor (MCT); TP, true positive.
https://doi.org/10.1371/journal.pone.0224945.t002
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Cyto-histological correlation
Following the tabulation of cytological and histological diagnoses (S1 Table), 36 cases (46.15%)
were classified as TP, 21 (26.92%) were TN, 20 (25.64%) were FN, and 1 (1.28%) was a FP
(Table 3).
The FP case had a cytological diagnosis of lymphoma that corresponded histologically to a
purulent bacterial splenitis (in this case the full spleen was available for analysis and no tumor
was found; however, severe marginal zone hyperplasia was present).
Neoplastic and non-neoplastic lesions were correctly identified in 57/78 cases (Table 3),
therefore overall accuracy of cytology was 73.08% (Table 4). Sensitivity of cytology in the diag-
nosis of splenic neoplasms was 64.29%, specificity was 95.45%, positive predictive value was
97.30%, and negative predictive value was 51.22% (Table 4). Positive and negative likelihood
ratios were 14.14 and 0.37, respectively (Table 4).
According to Cohen’s test the level of agreement was considered as “moderate”, with a κ
value of 0.473 corresponding to a standard error of 0.086.
The distribution of TP and FN cases for each tumor type is reported in Table 1. The sensi-
tivity of cytology in the diagnosis of each neoplastic subcategory was 100% for MCT, CARC
and ORCT, 75% for HES, 75% for HS, 71.43% for STS, 50% for LYM, and 0% for BSTT
included in the study. Further details regarding complete and partial agreement between
cytological and histological diagnoses as well as confidence intervals of sensitivity value for
each tumor type are listed in Table 1. Chi-square analysis of cytological sensitivity was applica-
ble only to HES, HS, STS, and LYM. No statistically significant sensitivity differences were
observed (p-value ranging from 0.1506 to 1.0).
Table 3. Cytological-histological correlation categories.
Diagnosis Histology: neoplastic Histology: non-neoplastic Total
Cytology: neoplastic 36 (TP) 1 (FP) 37
Cytology: non-neoplastic 20 (FN) 21 (TN) 41
Total 56 22 78
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
https://doi.org/10.1371/journal.pone.0224945.t003
Table 4. Prevalence of neoplastic lesions, with point estimate and 95% confidence interval of diagnostic accuracy
indexes, likelihood ratios and Cohen’s k.
Diagnostic accuracy index Value Confidence Interval (95%)
Prevalence 71.79% 60.47%–81.41%







K value 0.473 0.304–0.643
NLR, negative likelihood ratio; NPV, negative predictive value; PLR, positive likelihood ratio; PPV, positive
predictive value.
https://doi.org/10.1371/journal.pone.0224945.t004
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The proportion of TP and FN cases with nodular or diffuse pattern for each tumor type are
reported in Table 2. Sensitivity of cytology in the diagnosis of neoplastic lesions in general
according to their distribution pattern was 60.47% for nodular and 75% for diffuse neoplasms,
with no statistically significant difference between the two values (p = 0.3593). For some tumor
types the sensitivity of cytology on the basis of the distribution pattern was not calculated,
given that only nodular (BSTT, STS, HS, CARC) or diffuse (ORCT) neoplastic lesions were
represented in these categories. Sensitivity in the diagnosis of nodular and diffuse lymphomas
was for both 50%, with no statistically significant difference between the two values (p = 1.0).
Sensitivity for nodular angiosarcomas was 71.43% and 100% for diffuse angiosarcomas, while
sensitivity for both nodular and diffuse mast cell tumors was 100%. Considering these results,
Chi-square analysis of sensitivity on the basis of the distribution pattern was not performed for
angiosarcomas and mast cell tumors.
Discussion
In this study we report overall accuracy, sensitivity, specificity, positive and negative predic-
tive values of cytology for the diagnosis of canine splenic neoplasms. Similar studies [8,23–
25,31–33] have limited the evaluation of cytological diagnostic accuracy to overall agreement
with histopathology, hampering comparison with our results. Our study has evidenced a
moderate overall accuracy of cytology. Specifically, although this technique had a high speci-
ficity and positive predictive value for the diagnosis of splenic neoplasia, sensitivity and
negative predictive value were lower, indicating that cytological diagnosis of splenic neopla-
sia is reliable, but a negative result cannot be used to exclude the possibility of splenic
neoplasia.
According to overall accuracy and Cohen’s k values, cytology is not a reliable alternative to
histopathology in the definitive diagnosis of splenic tumors in most cases. When compared
with previous studies, our overall accuracy value (73.08%) laid in between the higher range of
83.87–100% [23–25] and the lower 38–69.7% range [8,31–33] reported in other studies. To
allow comparison, the overall accuracy (intended as the sum of complete and partial diagnostic
agreements) was calculated from the raw data of previously published caseloads [8,23–25,31–
33] when not made explicit in the corresponding manuscript.
Low sensitivity and negative predictive value of this study indicate that a cytology negative
for neoplasia should prompt further investigations to confirm a dog to be truly free from neo-
plastic disease. This contrasts with our initial hypothesis that cytology may represent a useful
tool to avoid unnecessary splenectomy. Instead, high specificity and positive predictive value
identify cytology as a good and reliable tool to rule in the diagnosis of splenic neoplasia with a
high degree of confidence. In practical terms, a cytology positive for neoplasia may lead to a
faster surgical treatment, avoiding lag times and higher costs associated with application of
diagnostic imaging techniques such as contrast-enhanced ultrasound and computed tomogra-
phy (CT) [1,56]. Our results are in line with studies evaluating diagnostic accuracy of cytology
applied to various organs in dogs [31,32,35,36,54], with sensitivity and negative predictive
value generally lower than specificity and positive predictive value, respectively.
Regarding the reliability of cytology in the diagnosis of specific tumor types, the lack of sta-
tistically significant differences between subcategories may be related to an imbalance in the
number of cases for each tumor type. Also, our results may be influenced by the tumor cell
type evaluated, since exfoliation rate varies substantially between round cell, epithelial and
mesenchymal tumors [30,31,35,53]. Specifically, mesenchymal tumors have the lowest ten-
dency to exfoliate [30,31,35,53] explaining the low sensitivity in diagnosing benign mesenchy-
mal tumors. Moreover, identification of vascular tumors (i.e. angiomas and HES) among false
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negative cases is not surprising since the architecture of these tumors often leads to significant
peripheral blood contamination in aspirates [4,30,32,57]. The low sensitivity of cytology in the
diagnosis of splenic lymphomas relates to the specific distribution of tumor types in the spleen,
where indolent nodular lymphomas (i.e. mantle cell lymphoma and marginal zone lymphoma)
are frequent as was in this caseload. These are nodular lymphomas composed of small to
medium sized cells with minimal atypia and a low mitotic rate [49,58]. Thus, mantle cell lym-
phoma and marginal zone lymphoma can be easily misinterpreted as reactive lymphoid hyper-
plasia on cytology, and histopathology is often necessary for a definitive diagnosis that relies
on the evaluation of tumor architecture [49].
Although not statistically significant, our results paralleled those of previous reports identi-
fying higher cytological accuracy in the diagnosis of diffuse compared to focal lesions
[23,32,57].
One false positive diagnosis of neoplasia (i.e. lymphoma) was included in this study. Splenic
marginal zone hyperplasia is a common finding in dogs [49,59], and cytological sampling
from these areas may result in a monomorphic specimen mimicking marginal zone lym-
phoma. This is a risk that pathologists have to bear in mind; thus the diagnosis of nodular low-
grade lymphoma should be supported by histological evaluation of architectural changes, espe-
cially in dogs. A recent report [60] has demonstrated a high overall concordance between his-
topathology, immunohistochemistry and PCR for antigen receptor rearrangement (PARR) in
the diagnosis of marginal zone lymphoma, mantle cell lymphoma and lymphoid or complex
nodular hyperplasia. Therefore, further development of combined methods also applicable to
cytological specimens may provide a less invasive and more valuable diagnostic approach to
the diagnosis of splenic nodular lymphoid lesions.
Although histopathology is generally considered the diagnostic reference standard
[24,31,33,35,36], several limitations should also be considered for this technique in the diagno-
sis of splenic tumors. Specifically, the diagnosis of splenic hematomas and hemangiosarcomas
is considered difficult, especially if spleens are not submitted entirely and if adequate samples
from the margin of the lesion are not collected [2,3,5]. Noteworthy, splenic hematomas and
HES may not be grossly distinguishable [2,3,5,23,61], and the first may represent a component
of the latter [61].
The current study is characterized by several limitations, mainly due to its retrospective
nature. One major limit was the inclusion of specimens obtained by different sampling tech-
niques, with a high number of impression smears collected from both surgical biopsies and
necropsies. Additionally, the inclusion of splenic cytological samples from necropsies and the
university setting of this work may have further biased the study toward cases with a more
aggressive behavior and with features of malignancy easier to diagnose. This may not reflect
daily clinical practice in which FNA is the most common sampling technique to pre-opera-
tively assess splenic lesions. Also, as previously observed [31,53], different sampling methods
may have resulted in an improvement of sensitivity of cytology in this study, especially for
those neoplasms characterized by low exfoliation rate. On the other hand, this observation can
be viewed also in positive terms. Indeed, in a practical setting the preliminary evaluation of
surgical biopsies or entire spleens by cytology prior to fixation could be implemented to facili-
tate the diagnosis and to reduce turnaround time. Additionally, this approach can provide
pathologists with material useful not only for a preliminary diagnosis, but also for immunocy-
tochemistry and for PARR on fresh specimens.
Despite this caseload being larger than previously reported ones, the small number of cases
evaluated may explain the relatively wide confidence intervals observed around point estimates
of our diagnostic accuracy indexes. Results may have been further biased by the inclusion
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criteria applied in the current study, leading to the exclusion of more than 90% cytological
samples of canine spleen in our archives.
Unfortunately, full agreement with STARD guidelines could not be obtained in this study
since the type of treatment administered between cytological and histological sampling, and
the incidence of adverse events following splenic sampling, could not be retrieved from our
electronic archives.
In conclusion, to the best of our knowledge, this is the first study conjunctively reporting
overall accuracy, sensitivity, specificity, positive and negative predictive values of cytology in
the diagnosis of canine splenic neoplasms compared to histopathology. Diagnostic accuracy
indexes identified limitations of negative cytological results in excluding a dog to be truly free
from neoplasia; however, high specificity and positive predictive value highlighted cytology as
a valuable tool in the diagnostic approach to splenic neoplasms.
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